- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Industry News: Definiens takes CAD into the lymph nodes
Definiens introduced its latest CAD system as a way to judge the effects of therapy on some cancer patients.
Definiens introduced its latest CAD system as a way to judge the effects of therapy on some cancer patients. Dubbed LymphExpert, the CAD technology helps detect the metastatic spread of cancer by better identifying, analyzing, and measuring volumetric changes in the size of lymph nodes. The CAD software promises to save time and make study results more consistent by automating segmentation and analysis of the nodes.
LymphExpert is brought in after a radiologist has manually detected lymph nodes in a CT image, automatically segmenting and quantifying the nodes according to established guidelines, then reconstructing a volumetric image. Definiens contends that a precise 3D picture of a lymph node's growth or shrinkage over time indicates cancer progression or remission. The Munich-based company, founded in 1986 by Nobel Laureate Gerd Binnig, develops "cognitive emulation" software that automates and quantifies challenging image analysis challenges.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
